Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast.

Felicio PS, Alemar B, Coelho AS, Berardinelli GN, Melendez ME, Lengert AVH, Miche Lli RD, Reis RM, Fernandes GC, Ewald IP, Bittar CM, Netto CBO, Artigalas O, Peixoto A, Pinheiro M, Teixeira MR, Vargas FR, Dos Santos ACE, Moreira MAM, Ashton-Prolla P, Palmero EI.

Cancer Genet. 2018 Dec;228-229:93-97. doi: 10.1016/j.cancergen.2018.09.001. Epub 2018 Oct 6.

PMID:
30553478
2.

From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America.

Vaccaro CA, López-Kostner F, Adriana DV, Palmero EI, Rossi BM, Antelo M, Solano A, Carraro DM, Forones NM, Bohorquez M, Lino-Silva LS, Buleje J, Spirandelli F, Abe-Sandes K, Nascimento I, Sullcahuaman Y, Sarroca C, Gonzalez ML, Herrando AI, Alvarez K, Neffa F, Galvão HC, Esperon P, Golubicki M, Cisterna D, Cardoso FC, Torrezan GT, Junior SA, Pimenta CAM, da Cruz Formiga MN, Santos E, Sá CU, Oliveira EP, Fujita R, Spirandelli E, Jimenez G, Guindalini RSC, de Azevedo RGMV, Bueno LSM, Dos Santos Nogueira ST, Loarte MT, Padron J, Del Carmen Castro-Mujica M, Del Monte JS, Caballero C, Peña CMM, Pinto J, Barletta-Carrillo C, Melva GA, Piñero T, Beltran PM, Ashton-Prolla P, Rodriguez Y, Quispe R, Rossi NT, Martin C, Chialina S, Kalfayan PG, Bazo-Alvarez JC, Cañete AR, Dominguez-Barrera C, Nuñez L, Da Silva SD, Balavarca Y, Wernhoff P, Plazzer JP, Møller P, Hovig E, Dominguez-Valentin M; in collaboration with GETH.

Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31920. [Epub ahead of print] Review.

PMID:
30303536
3.

The germline mutational landscape of BRCA1 and BRCA2 in Brazil.

Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, Galvão HCR, Reis RM, de Pádua Souza C, Campacci N, Achatz MI, Brianese RC, da Cruz Formiga MN, Makdissi FB, Vargas FR, Evangelista Dos Santos AC, Seuanez HN, Lobo de Souza KR, Netto CBO, Santos-Silva P, da Silva GS, Burbano RMR, Santos S, Assumpção PP, Bernardes IMM, Machado-Lopes TMB, Bomfim TF, Toralles MBP, Nascimento I, Garicochea B, Simon SD, Noronha S, de Lima FT, Chami AM, Bittar CM, Bines J, Artigalas O, Esteves-Diz MDP, Lajus TBP, Gifoni ACLVC, Guindalini RSC, Cintra TS, Schwartz IVD, Bernardi P, Miguel D, Nogueira STDS, Herzog J, Weitzel JN, Ashton-Prolla P.

Sci Rep. 2018 Jun 15;8(1):9188. doi: 10.1038/s41598-018-27315-2.

4.

Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?

Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, Schwartz IVD, Coffa J, Alves Camey S, Weitzel J, Ashton-Prolla P.

PLoS One. 2018 May 11;13(5):e0197529. doi: 10.1371/journal.pone.0197529. eCollection 2018.

5.

Clinical and molecular characterization of neurofibromatosis in southern Brazil.

Rosset C, Vairo F, Cristina Bandeira I, Fonini M, Netto CBO, Ashton-Prolla P.

Expert Rev Mol Diagn. 2018 Jun;18(6):577-586. doi: 10.1080/14737159.2018.1468256. Epub 2018 Apr 27.

PMID:
29685074
6.

The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer.

Reinert T, Nogueira-Rodrigues A, Kestelman FP, Ashton-Prolla P, Graudenz MS, Bines J.

Clin Breast Cancer. 2018 Aug;18(4):e587-e594. doi: 10.1016/j.clbc.2018.03.006. Epub 2018 Mar 12. Review.

PMID:
29680194
7.

Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

Schneider NB, Pastor T, Paula AE, Achatz MI, Santos ÂRD, Vianna FSL, Rosset C, Pinheiro M, Ashton-Prolla P, Moreira MÂM, Palmero EI; Brazilian Lynch Syndrome Study Group.

Cancer Med. 2018 May;7(5):2078-2088. doi: 10.1002/cam4.1316. Epub 2018 Mar 25.

8.

BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?

Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, Schwartz IVD, Coffa J, Alves Camey S, Weitzel J, Ashton-Prolla P.

PLoS One. 2017 Nov 21;12(11):e0187630. doi: 10.1371/journal.pone.0187630. eCollection 2017. Erratum in: PLoS One. 2018 May 11;13(5):e0197529.

9.

Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis.

Rosset C, Vairo F, Bandeira IC, Correia RL, de Goes FV, da Silva RTB, Bueno LSM, de Miranda Gomes MCS, Galvão HCR, Neri JICF, Achatz MI, Netto CBO, Ashton-Prolla P.

PLoS One. 2017 Oct 2;12(10):e0185713. doi: 10.1371/journal.pone.0185713. eCollection 2017.

10.

Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing.

Soares BL, Brant AC, Gomes R, Pastor T, Schneider NB, Ribeiro-Dos-Santos Â, de Assumpção PP, Achatz MIW, Ashton-Prolla P, Moreira MAM.

Fam Cancer. 2018 Jul;17(3):387-394. doi: 10.1007/s10689-017-0043-5.

PMID:
28932927
11.

A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

Rossi BM, Palmero EI, López-Kostner F, Sarroca C, Vaccaro CA, Spirandelli F, Ashton-Prolla P, Rodriguez Y, de Campos Reis Galvão H, Reis RM, Escremim de Paula A, Capochin Romagnolo LG, Alvarez K, Della Valle A, Neffa F, Kalfayan PG, Spirandelli E, Chialina S, Gutiérrez Angulo M, Castro-Mujica MDC, Sanchez de Monte J, Quispe R, da Silva SD, Rossi NT, Barletta-Carrillo C, Revollo S, Taborga X, Morillas LL, Tubeuf H, Monteiro-Santos EM, Piñero TA, Dominguez-Barrera C, Wernhoff P, Martins A, Hovig E, Møller P, Dominguez-Valentin M.

BMC Cancer. 2017 Sep 5;17(1):623. doi: 10.1186/s12885-017-3599-4.

12.

p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.

Macedo GS, Vieira IA, Vianna FSL, Alemar B, Giacomazzi J, Brandalize APC, Caleffi M, Volc SM, de Campos Reis Galvão H, Palmero EI, Achatz MI, Ashton-Prolla P.

Fam Cancer. 2018 Apr;17(2):269-274. doi: 10.1007/s10689-017-0028-4.

PMID:
28756477
13.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

14.

TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review.

Rosset C, Netto CBO, Ashton-Prolla P.

Genet Mol Biol. 2017 Jan-Mar;40(1):69-79. doi: 10.1590/1678-4685-GMB-2015-0321. Epub 2017 Feb 20.

15.

Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Villacis RAR, Basso TR, Canto LM, Pinheiro M, Santiago KM, Giacomazzi J, de Paula CAA, Carraro DM, Ashton-Prolla P, Achatz MI, Rogatto SR.

J Mol Med (Berl). 2017 May;95(5):523-533. doi: 10.1007/s00109-017-1507-7. Epub 2017 Jan 16.

PMID:
28093616
16.

Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.

Alemar B, Herzog J, Brinckmann Oliveira Netto C, Artigalás O, Schwartz IVD, Matzenbacher Bittar C, Ashton-Prolla P, Weitzel JN.

Cancer Genet. 2016 Sep;209(9):417-422. doi: 10.1016/j.cancergen.2016.06.008. Epub 2016 Jun 20.

PMID:
27425403
17.

Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing.

Ferreira CG, Achatz MI, Ashton-Prolla P, Begnami MD, Marchini FK, Stefani SD.

Lancet Oncol. 2016 Aug;17(8):e363-e370. doi: 10.1016/S1470-2045(16)30171-1. Review.

PMID:
27511160
18.

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.

Ewald IP, Cossio SL, Palmero EI, Pinheiro M, Nascimento IL, Machado TM, Sandes KA, Toralles B, Garicochea B, Izetti P, Pereira ML, Bock H, Vargas FR, Moreira MÂ, Peixoto A, Teixeira MR, Ashton-Prolla P.

Genet Mol Biol. 2016 Apr-Jun;39(2):223-31. doi: 10.1590/1678-4685-GMB-2014-0350.

19.

The Brazilian Hereditary Cancer Network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil.

Ashton-Prolla P, Seuanez HN.

Genet Mol Biol. 2016 Jun 3;39(2):163-5. doi: 10.1590/1678-4685-GMB-2014-0373. No abstract available.

20.

Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53.

Fitarelli-Kiehl M, Macedo GS, Schlatter RP, Koehler-Santos P, Matte Uda S, Ashton-Prolla P, Giacomazzi J.

Genet Mol Biol. 2016 Jun 3;39(2):203-9. doi: 10.1590/1678-4685-GMB-2014-0351.

21.

Commentary regarding Schayek et al., entitled "The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil".

Sales Luiz Vianna F, Alemar B, Achatz MI, Camey SA, Ashton-Prolla P.

Cancer Genet. 2016 Jun;209(6):282-3. doi: 10.1016/j.cancergen.2016.04.002. Epub 2016 Apr 27. No abstract available.

PMID:
27262228
22.

The Development of the Study of Hereditary Cancer in South America.

Rossi BM, Sarroca C, Vaccaro C, Lopez F, Ashton-Prolla P, Ferreira Fde O, Santos EM.

Genet Mol Biol. 2016 May 24;39(2):166-7. doi: 10.1590/1678-4685-GMB-2014-0366. No abstract available.

23.

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.

Palmero EI, Alemar B, Schüler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, Santos PK, Ribeiro PL, Oliveira CB, Calvez-Kelm FL, Tavtigian S, Cossio SL, Giugliani R, Caleffi M, Ashton-Prolla P.

Genet Mol Biol. 2016 May 24;39(2):210-22. doi: 10.1590/1678-4685-GMB-2014-0363. Erratum in: Genet Mol Biol. 2017 Mar 16;:0.

24.

Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.

Escobar GF, Arraes JA, Bakos L, Ashton-Prolla P, Giugliani R, Callegari-Jacques SM, Santos S, Bakos RM.

Melanoma Res. 2016 Aug;26(4):348-53. doi: 10.1097/CMR.0000000000000267.

PMID:
27145040
25.

Retinoblastoma in a pediatric oncology reference center in Southern Brazil.

Selistre SGA, Maestri MK, Santos-Silva P, Schüler-Faccini L, Guimarães LSP, Giacomazzi J, Evangelista Júnior MC, Ashton-Prolla P.

BMC Pediatr. 2016 Apr 3;16:48. doi: 10.1186/s12887-016-0579-9.

26.

Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.

Macedo GS, Araujo Vieira I, Brandalize AP, Giacomazzi J, Inez Palmero E, Volc S, Rodrigues Paixão-Côrtes V, Caleffi M, Silva Alves M, Achatz MI, Hainaut P, Ashton-Prolla P.

Cancer Genet. 2016 Mar;209(3):97-106. doi: 10.1016/j.cancergen.2015.12.012. Epub 2016 Jan 7.

PMID:
26823150
27.

miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review.

Alemar B, Gregório C, Ashton-Prolla P.

Biomark Insights. 2015 Dec 13;10:113-24. doi: 10.4137/BMI.S27679. eCollection 2015. Review.

28.

Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma.

Puig S, Potrony M, Cuellar F, Puig-Butille JA, Carrera C, Aguilera P, Nagore E, Garcia-Casado Z, Requena C, Kumar R, Landman G, Costa Soares de Sá B, Gargantini Rezze G, Facure L, de Avila AL, Achatz MI, Carraro DM, Duprat Neto JP, Grazziotin TC, Bonamigo RR, Rey MC, Balestrini C, Morales E, Molgo M, Bakos RM, Ashton-Prolla P, Giugliani R, Larre Borges A, Barquet V, Pérez J, Martínez M, Cabo H, Cohen Sabban E, Latorre C, Carlos-Ortega B, Salas-Alanis JC, Gonzalez R, Olazaran Z, Malvehy J, Badenas C.

Genet Med. 2016 Jul;18(7):727-36. doi: 10.1038/gim.2015.160. Epub 2015 Dec 17.

29.

Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p.

Paskulin DD, Giacomazzi J, Achatz MI, Costa S, Reis RM, Hainaut P, dos Santos SE, Ashton-Prolla P.

PLoS One. 2015 Nov 30;10(11):e0143262. doi: 10.1371/journal.pone.0143262. eCollection 2015.

30.

Costs of genetic testing: Supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologies.

Schlatter RP, Matte U, Polanczyk CA, Koehler-Santos P, Ashton-Prolla P.

Genet Mol Biol. 2015 Jul-Sep;38(3):332-7. doi: 10.1590/S1415-475738320140204. Epub 2015 Aug 21.

31.

Erratum: CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families.

Abud J, Prolla JC, Koehler-Santos P, Ashton-Prolla P; Study Group on Hereditary Breast and Colorectal Cancer.

Arq Gastroenterol. 2015 Jan-Mar;52(1):VIII. doi: 10.1590/S0004-28032015000100017.

32.

Genetic Variations in the TP53 Pathway in Native Americans Strongly Suggest Adaptation to the High Altitudes of the Andes.

Jacovas VC, Rovaris DL, Peréz O, de Azevedo S, Macedo GS, Sandoval JR, Salazar-Granara A, Villena M, Dugoujon JM, Bisso-Machado R, Petzl-Erler ML, Salzano FM, Ashton-Prolla P, Ramallo V, Bortolini MC.

PLoS One. 2015 Sep 18;10(9):e0137823. doi: 10.1371/journal.pone.0137823. eCollection 2015.

33.

miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.

Alemar B, Izetti P, Gregório C, Macedo GS, Castro MA, Osvaldt AB, Matte U, Ashton-Prolla P.

Pancreas. 2016 Jan;45(1):84-92. doi: 10.1097/MPA.0000000000000383.

PMID:
26262588
34.

Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.

Giacomazzi CR, Giacomazzi J, Netto CB, Santos-Silva P, Selistre SG, Maia AL, Oliveira VZ, Camey SA, Goldim JR, Ashton-Prolla P.

Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):282-9. doi: 10.1590/1806-9282.61.03.282. Review.

35.

Erratum to: Genomic analysis in the clinic: benefits and challenges for health care professionals and patients in Brazil.

Ashton-Prolla P, Goldim JR, Vairo FP, da Silveira Matte U, Sequeiros J.

J Community Genet. 2015 Jul;6(3):285. doi: 10.1007/s12687-015-0246-0. No abstract available.

36.

Vitamin D Status and VDR Genotype in NF1 Patients: A Case-Control Study from Southern Brazil.

Souza Mario Bueno L, Rosset C, Aguiar E, Pereira Fde S, Izetti Ribeiro P, Scalco R, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Gischkow Rucatti G, Chies JA, Camey SA, Ashton-Prolla P.

Int J Endocrinol. 2015;2015:402838. doi: 10.1155/2015/402838. Epub 2015 Jun 16.

37.

Genetic information and biobanking: a Brazilian perspective on biological and biographical issues.

Fernandes MS, Ashton-Prolla P, de Moraes LS, Matte ÚS, Goldim JR, Martins-Costa J.

J Community Genet. 2015 Jul;6(3):295-9. doi: 10.1007/s12687-015-0242-4. Epub 2015 Jun 13.

38.

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.

Artigalás O, Vanni T, Hutz MH, Ashton-Prolla P, Schwartz IV.

BMC Med. 2015 Jun 11;13:139. doi: 10.1186/s12916-015-0373-9.

39.

Genomic analysis in the clinic: benefits and challenges for health care professionals and patients in Brazil.

Ashton-Prolla P, Goldim JR, Vairo FP, da Silveira Matte U, Sequeiros J.

J Community Genet. 2015 Jul;6(3):275-83. doi: 10.1007/s12687-015-0238-0. Epub 2015 Jun 4.

40.

Knowledge about breast cancer and hereditary breast cancer among nurses in a public hospital.

Prolla CM, da Silva PS, Netto CB, Goldim JR, Ashton-Prolla P.

Rev Lat Am Enfermagem. 2015 Jan-Feb;23(1):90-7. doi: 10.1590/0104-1169.0185.2529. English, Portuguese, Spanish.

41.

The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.

Fitarelli-Kiehl M, Giacomazzi J, Santos-Silva P, Graudenz MS, Palmero EI, Michelli RA, Achatz MI, de Toledo Osório CA, de Faria Ferraz VE, Picanço CG, Ashton-Prolla P.

Fam Cancer. 2015 Jun;14(2):333-6. doi: 10.1007/s10689-015-9779-y.

PMID:
25564201
42.

Brain imaging and genetic risk in the pediatric population, part 2: congenital malformations of the central nervous system.

Longo MG, Félix TM, Ashton-Prolla P, Vedolin LM.

Neuroimaging Clin N Am. 2015 Feb;25(1):53-67. doi: 10.1016/j.nic.2014.09.003.

PMID:
25476512
43.

A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.

Brandalize AP, Schüler-Faccini L, Hoffmann JS, Caleffi M, Cazaux C, Ashton-Prolla P.

BMC Cancer. 2014 Nov 19;14:850. doi: 10.1186/1471-2407-14-850.

44.

Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: A case-control study.

Cibeira GH, Giacomazzi J, Aguiar E, Schneider S, Ettrich B, DE Souza CI, Camey S, Caleffi M, Weber B, Ashton-Prolla P, Moriguchi EH.

Mol Clin Oncol. 2014 Nov;2(6):1009-1015. Epub 2014 Aug 1.

45.

Fabry disease: Evidence for a regional founder effect of the GLA gene mutation 30delG in Brazilian patients.

de Alencar DO, Netto C, Ashton-Prolla P, Giugliani R, Ribeiro-Dos-Santos Â, Pereira F, Matte U, Santos N, Santos S.

Mol Genet Metab Rep. 2014 Sep 26;1:414-421. eCollection 2014.

46.

Interaction between TP63 and MDM2 genes and the risk of recurrent pregnancy loss.

Fraga LR, Boquett JA, Dutra CG, Vianna FS, Heck C, Gonçalves RO, Paskulin DD, Costa OL, Ashton-Prolla P, Sanseverino MT, Schuler-Faccini L.

Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:7-10. doi: 10.1016/j.ejogrb.2014.07.044. Epub 2014 Aug 24.

PMID:
25218545
47.

The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer.

Giacomazzi J, Correia RL, Palmero EI, Gaspar JF, Almeida M, Portela C, Camey SA, Monteiro A, Pinheiro M, Peixoto A, Teixeira MR, Reis RM, Ashton-Prolla P.

Breast J. 2014 Sep-Oct;20(5):534-6. doi: 10.1111/tbj.12308. Epub 2014 Jul 23.

PMID:
25052705
48.

Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.

Giacomazzi J, Graudenz MS, Osorio CA, Koehler-Santos P, Palmero EI, Zagonel-Oliveira M, Michelli RA, Scapulatempo Neto C, Fernandes GC, Achatz MI, Martel-Planche G, Soares FA, Caleffi M, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P.

PLoS One. 2014 Jun 17;9(6):e99893. doi: 10.1371/journal.pone.0099893. eCollection 2014.

49.

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.

Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, Lenz G, Roesler R, Schwartsmann G, Osvaldt AB, Hainaut P, Ashton-Prolla P.

Invest New Drugs. 2014 Oct;32(5):783-94. doi: 10.1007/s10637-014-0090-9. Epub 2014 May 20.

PMID:
24838627
50.

Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.

Ashton-Prolla P, Vargas FR.

Genet Mol Biol. 2014 Mar;37(1 Suppl):234-40.

Supplemental Content

Loading ...
Support Center